[Effects of budesonide on HIF-1α and VEGF expression and airway remodeling in an asthmatic mouse model].
OBJECTIVE
To study the effects of budesonide on hypoxia inducible factor 1α(HIF-1α) and vascular endothelial growth factor (VEGF) expression, angiogenesis and airway remodeling in the chronic asthmatic mouse model.


METHODS
Thirty female BALB/c mice were randomly divided into normal control, asthma model and treatment groups (10 in each group).The asthmatic mouse model was established via OVA challenge test. Mice in the treatment group were administered with aerosol budesonide (100 μg/kg) an hour before the OVA challenge test from the 28th day. Mice in the control group were treated with PBS instead of OVA. Hematoxylin and eosin staining was performed to observe thickness of the airway wall. Masson staining was used for examing collagen deposition of lung tissues. Angiogenesis and HIF-1α and VEGF expression were measured using immunohistochemistry and Western blot. The relationship of airway wall thickness and vessel area to HIF-1α and VEGF expression was investigated.


RESULTS
Vessel area, collagen deposition of lung tissues and airway wall thickness increased in the asthma model group. Levels of HIF-1α and VEGF were also elevated. Administration of budesonide significantly reduced angiogenesis, collagen deposition of lung tissues and airway wall thickening, as well as expression of HIF-1α and VEGF. The vessel area and airway wall thickness were positively correlated with expression of HIF-1α and VEGF. A positive correlation was also found between the expression of HIF-1α and VEGF.


CONCLUSIONS
Budesonide can decease angiogenesis and airway remodeling by inhibiting  HIF-1α and VEGF expression in asthmatic mice.
Department of Pediatrics, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
Yan
Y
Sun
Jin-Rong
JR
Wang
Xiu-Zhen
XZ
Han
Hua-Bing
HB
Li
Li-Feng
LF
Sun
Xing
X
Chen
Yi-Zhen
YZ
Feng
D056151:Airway Remodeling / Q000187:drug effects*; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001980:Bronchi / Q000473:pathology; D001993:Bronchodilator Agents / Q000494:pharmacology*; D019819:Budesonide / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000032:analysis*; D051379:Mice; D008807:Mice, Inbred BALB C; D018919:Neovascularization, Physiologic; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
D001993:Bronchodilator Agents; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; D019819:Budesonide